A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings

被引：0
|
作者：
Jonker, D. J.
Rosen, L. S.
Sawyer, M.
Wilding, G.
Noberasco, C.
Jayson, G.
Rustin, G.
McArthur, G.
Velasquez, L.
Galbraith, S.
机构：
[1] Ottawa Reg Canc Ctr, Ottawa, ON, Canada
[2] Premiere Oncol, Santa Monica, CA USA
[3] Cross Canc Inst, Edmonton, AB, Canada
[4] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[5] Ist Europeo Oncol, Milan, Italy
[6] Christie Hosp, Manchester, Lancs, England
[7] Mt Vernon Canc Ctr, Northwood, Middx, England
[8] Peter MacCallum Canc Ctr, East Melbourne, Australia
[9] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
    Garrett, C. R.
    Siu, L. L.
    Giaccone, G.
    El-Khoueiry, A.
    Marshall, J.
    LoRusso, P.
    Velasquez, L.
    Kollia, G.
    He, P.
    Feltquate, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
    Garrett, C. R.
    Siu, L. L.
    El-Khoueiry, A. B.
    Buter, J.
    Rocha-Lima, C. M.
    Marshall, J. L.
    Kollia, G.
    Velasquez, L.
    Syed, S.
    Feltquate, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
    Rosen, L. S.
    Wilding, G.
    Sweeney, C.
    Casale, D.
    Kollia, G.
    Wu, C.
    Ayers, M.
    Hill, C.
    Galbraith, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 133S - 133S
  • [4] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
  • [5] Phase I study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors
    Hurwitz, H.
    LoRusso, P.
    Shapiro, G. I.
    Wolanksi, A.
    Chemidlin, J.
    Masson, E.
    Syed, S.
    Kollia, G.
    Conlon, K.
    EJC SUPPLEMENTS, 2008, 6 (12): : 135 - 135
  • [6] Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors.
    Faivre, Sandrine J.
    Olszanski, Anthony J.
    Weigang-Koehler, Karin
    Riess, Hanno
    Peng, Guangbin
    Callies, Sophie
    Benhadji, Karim Adnane
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors
    Lal, R.
    Camidge, D. R.
    George, S.
    Demetri, G. D.
    Eckhardt, S. G.
    Stephens, A.
    Chick, J.
    Boinpally, R.
    Kaye, S. B.
    Scurr, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases
    Platero, S.
    Mokliatchouk, O.
    Jayson, G. C.
    Jonker, D. J.
    Rosen, L. S.
    Luroe, S.
    Kelsey, J.
    Feltquate, D.
    Velasquez, L.
    Galbraith, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors
    Macarulla, T.
    Rodriguez-Braun, E.
    Tabernero, J.
    Rosello, S.
    Baselga, J.
    Lee, Y.
    Manfredi, M.
    Liu, H.
    Fingert, H.
    Cervantes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345